foscarnet has been researched along with Water-Electrolyte Imbalance in 4 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Water-Electrolyte Imbalance: Disturbances in the body's WATER-ELECTROLYTE BALANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P = ." | 9.08 | Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995) |
| "Although foscarnet is a promising alternative for the treatment of cytomegalovirus (CMV) infection, its toxicity can be significant in patients with advanced age." | 7.74 | Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. ( Hori, A; Kami, M; Kato, D; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Morinaga, S; Murashige, N; Narimatsu, H; Shibata, T; Taniguchi, S; Wake, A; Yuji, K, 2007) |
| "Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P = ." | 5.08 | Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995) |
| "Although foscarnet is a promising alternative for the treatment of cytomegalovirus (CMV) infection, its toxicity can be significant in patients with advanced age." | 3.74 | Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. ( Hori, A; Kami, M; Kato, D; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Morinaga, S; Murashige, N; Narimatsu, H; Shibata, T; Taniguchi, S; Wake, A; Yuji, K, 2007) |
| "An AIDS patient experienced an exacerbation of cytomegalovirus retinitis and was treated with foscarnet." | 3.68 | Foscarnet-induced severe hypomagnesemia and other electrolyte disorders. ( Gearhart, MO; Sorg, TB, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Narimatsu, H | 1 |
| Kami, M | 1 |
| Kato, D | 1 |
| Matsumura, T | 1 |
| Murashige, N | 1 |
| Kusumi, E | 1 |
| Yuji, K | 1 |
| Hori, A | 1 |
| Shibata, T | 1 |
| Masuoka, K | 1 |
| Wake, A | 1 |
| Miyakoshi, S | 1 |
| Morinaga, S | 1 |
| Taniguchi, S | 1 |
| Gearhart, MO | 1 |
| Sorg, TB | 1 |
| Jayaweera, D | 1 |
| White, G | 1 |
| Moreno, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
1 trial available for foscarnet and Water-Electrolyte Imbalance
| Article | Year |
|---|---|
Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.
Topics: Acute Kidney Injury; Adolescent; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retin | 1995 |
3 other studies available for foscarnet and Water-Electrolyte Imbalance
| Article | Year |
|---|---|
Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation.
Topics: Adolescent; Adult; Aged; Antigens, Viral; Antiviral Agents; Cord Blood Stem Cell Transplantation; Cy | 2007 |
Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.
Topics: Adult; Cytomegalovirus Infections; Foscarnet; HIV Infections; Hospitals, Community; Hospitals, Teach | 1993 |
Pre-treatment with hydration and electrolytes may prevent dose limiting toxicities during foscarnet induction therapy.
Topics: Antiviral Agents; Cytomegalovirus Retinitis; Electrolytes; Foscarnet; Humans; Premedication; Prospec | 1995 |